Doxapram

Overview

Doxapram is a respiratory stimulant. Doxapram increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram inhibits TASK-1 , TASK-3 , TASK-1/TASK-3 heterodimeric channel function with EC 50 s of 410 nM, 37 μM, 9 μM, respectively. Doxapram inhibits the Ca²⁺-activated potassium current ( IC 50 ≈ 13 μM) and Ca²⁺-independent potassium current ( IC 50 ≈ 20 μM) in type I cells of the carotid body. Doxapram significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Potassium Channel

Product Information

• Catalog No.: HY-B0551
• CAS No.: 309-29-5
• Molecular Formula: C24H30N2O2
• Molecular Weight: 378.51
• Purity: 99.70%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.60 mM); Clear solution
• Availability: In-stock

Source

Original product source